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Across Europe, the outlook for women diagnosed with early 
breast cancer is likely to be far better now than at the start of my 
career. Effective screening programmes mean women are 
being diagnosed earlier, and greatly improved surgical 
techniques have also made a significant impact. Post-surgery, 
the evolution of adjuvant therapy has meant that we now have 
an armoury of effective treatments to stop breast cancer 
returning, although debate continues on how these treatments 
should be used for maximum benefit. 
The greatest concern for doctors, and for women who are being 
treated for early breast cancer, is that it may return, which 
ultimately means their disease is incurable. Although all patients 
are at risk of recurrence, the greatest risk is around 18 months 
after surgery and a level of risk remains for many years, 
particularly in hormone receptor positive early disease [1]. 
Combating recurrence is therefore one of the most important 
aspects of any treatment strategy and where the focus of 
clinical investigation has been for many years. 
Looking back at clinical trials shows how far the oncology world 
has come. The effect of oestrogen on breast cancer risk was 
first shown over 100 years ago when researchers found that 
removing the ovaries of women with breast cancer improved 
their chances of survival. Following this, the first anti-oestrogens 
were developed and it is now over 30 years since tamoxifen 
was found to delay breast cancer recurrence. In 1983, the 
breakthrough NATO trial confirmed the place of tamoxifen as a 
gold-standard treatment for post-menopausal women with early 
breast cancer, by reducing the risk of recurrence by around 
50% [2]. 
Following tamoxifen, aminoglutethimide was investigated as an 
anti-aromatase adjuvant treatment for early breast cancer, 
laying the first steps for aromatase inhibitors (AIs) [3] AIs are a 
revolutionary class of drugs that work by interrupting the 
production of oestrogen that can promote tumour growth in 
post-menopausal women. Anastrozole was the first of the so-
called new-generation aromatase inhibitors, introduced in 1995, 
followed by letrozole and exemestane in 1996 and 1999 
respectively, all of which now rival the efficacy of tamoxifen and 
have fewer serious side effects. 
Data from the ATAC (Arimidex, Tamoxifen, Alone, or in 
Combination) trial, one of the world's largest and longest-
running breast cancer trials, comparing five years of upfront 
anastrozole with tamoxifen, has further confirmed the place of 
anastrozole as a new gold-standard treatment for early breast 
cancer. Over a median follow-up of 100 months (>8 years), 
anastrozole significantly reduces the risk of recurrence 
compared with tamoxifen by 24% (p<0.0001) and improves 
disease-free survival by 15% [4]. One of the most important 
findings, however, was the significant 'carry-over' effect of the 
drug, that is anastrozole continues to benefit women even four 
years after treatment ends. It is not truly understood why the 
positive effect of the drug persists and continues to increase 
over time, compared with tamoxifen, although what we may be 
seeing is an effect against the formation of micro-metastases 
during treatment. To date, anastrozole is the only AI, which has 
demonstrated this carry-over benefit [4]. 
Other early breast cancer trials that have followed thousands of 
women over many years have also confirmed the benefits of AI 
treatment, indicating that five years of treatment with tamoxifen 
alone may be sub-optimal for all patients other than those at the 
lowest risk of recurrence. Recent survival data from BIG 1-98, 
albeit not statistically significant, suggest longer follow-up and 
meta-analytical approaches may be required in order to 
determine whether the efficacy advantages of the aromatase 
inhibitors over tamoxifen, in terms of recurrence risk reduction, 
will translate into breast cancer survival benefit [5]. 
The debate still remains, however, around when it is best to 
introduce an AI into a treatment regimen, that is upfront as initial 
adjuvant treatment, following 2–3 years of tamoxifen or to 
extend adjuvant treatment after five years of tamoxifen is 
completed. The Intergroup Exemestane Study (IES) reported 
that switching to exemestane after 2–3 years of treatment with 
tamoxifen significantly improved survival rates for the AI, 
although it should be remembered that a switching strategy may 
put patients at risk by starting with the inferior treatment at the 
time when risk of recurrence is highest and also expose patients 
to the risk of side effects from two different agents [6]. The BIG 
1-98 study suggested that upfront letrozole was superior to 
tamoxifen followed by letrozole [5]. 
To add to the evidence base, a number of investigations are 
underway to ascertain the optimal treatment period for adjuvant 
therapy. There is a clear rationale for continuing to treat with 
hormonal therapy, given that breast cancer recurrence remains 
a threat more than ten years after surgery. Preliminary results 
from the Adjuvant Tamoxifen Longer Against Shorter (ATLAS) 
study investigated the benefits of using tamoxifen beyond five 
years, although the accumulation of serious side effects during 
long-term tamoxifen use has led to questions around the 
effectiveness of this approach [7]. 
Ensuring women remain free from breast cancer for many years 
will continue to be a clinical challenge. In my view, the best 






















chance of protecting against recurrence is to commence 
treatment with the most effective adjuvant therapy at diagnosis, 
one that is well tolerated, has a well-understood safety profile, 
and means that fewer patients have to be told the devastating 
news that their breast cancer has recurred. Advancements in 
treatments and ongoing clinical debate will undoubtedly 
continue, but we can be certain that the evolution of hormonal 
treatments has secured the place of aromatase inhibitors for 
many years to come. 
 
Professor Tony Howell 
Tony Howell is a Professor of Medical Oncology in the Cancer 
Research UK Department of Medical Oncology, University of 
Manchester, at the Christie Hospital NHS Foundation Trust, 
Manchester, UK. After training in London and Birmingham and 
working for the Medical Research Council, he became the Head 
of the Medical Oncology Breast Service, Christie Hospital. His 
major interest is in all aspects of breast diseases, having 
published more than 472 papers in this area. He has received 











































1.  Saphner T and Tormey DC et al (1996) Annual hazard 
rates of recurrence for breast cancer after primary 
therapy J Clin Oncol 14 10 2738–46 PMID 8874335 
2.  Nolvadex Adjuvant Trial Organisation (1983) Controlled 
trial of tamoxifen as adjuvant agent in management of 
early breast cancer. Interim analysis at four years by 
Nolvadex Adjuvant Trial Organisation Lancet 321 8319 
257–61 PMID 6130291 10.1016/S0140-6736(83)91683-5 
3.  Schteingart DE and Cash R et al (1966) Amino-
glutethimide and metastatic adrenal cancer. Maintained 
reversal (six months) of Cushing's syndrome JAMA 198 
9 1007–10 PMID 5953457 10.1001/jama.198.9.1007 
4.  Forbes J, on behalf on the ATAC Trialist's Group (2008) 
ATAC: 100 month median follow-up shows continued 
superior efficacy and no excess fracture risk for 
anastrozole compared with tamoxifen after treatment
completion  Lancet Oncol 9  1 45–53  10.1016/S1470-
2045(07)70385-6 
5.  Breast International Group (BIG) 1-98 Collaborative Group 
,Thurlimann B, Keshaviah A, Coates AS et al (2005) A 
comparison of letrozole and tamoxifen in 
postmenopausal women with early breast cancer New 
Engl J Med 353 2747–57 PMID 16382061 
6.  Coombes R, Kilburn L et al (2007) Survival and safety of 
exemestane versus tamoxifen after 2–3 years' 
tamoxifen treatment (Intergroup Exemestane Study): a 
randomised controlled trial  Lancet  369  9561 559–70 
PMID 17307102 10.1016/S0140-6736(07)60200-1 
7.  Fisher B et al (2001) Five versus more than five years of 
tamoxifen for lymph node-negative breast cancer: 
updated findings from the National Surgical Adjuvant 
Breast and Bowel Project B-14 randomized trial J Natl 
Cancer Inst  93  9 684–90 PMID 11333290  10.1093/jnci/ 
93.9.684 
 4  www.ecancermedicalscience.com 
S
h
o
r
t
 
C
o
m
m
u
n
i
c
a
t
i
o
n
s